Effectiveness of TA-CD Vaccine in Treating Cocaine Dependent Individuals

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00142857
First received: September 1, 2005
Last updated: February 19, 2008
Last verified: February 2008
  Purpose

Cocaine dependence is a major public health problem; an effective treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to evaluate the effectiveness of the cocaine vaccine candidate TA-CD in treating cocaine dependent individuals.


Condition Intervention Phase
Cocaine-Related Disorders
Biological: TA-CD
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cocaine Vaccine for Methadone Maintained Patients

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Number of methadone maintained individuals who achieve 3 consecutive weeks of cocaine abstinence between Weeks 8 and 20

Estimated Enrollment: 125
Study Start Date: July 2003
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
TACD
Biological: TA-CD
Placebo Comparator: 2 Drug: placebo

Detailed Description:

Cocaine is a highly addictive stimulant that has high abuse potential. An effective drug to treat cocaine dependent individuals has yet to be found. Cocaine produces euphoric effects by blocking the re-uptake of neurotransmitters, such as dopamine, within the brain. The vaccine candidate TA-CD is a cocaine derivative coupled to recombinant cholera toxin B. It is designed to generate drug-specific antibodies that bind to cocaine and prevent it from travelling to the brain from the blood, thereby neutralizing its psychoaffective effect. The purpose of this study is to evaluate the effectiveness of TA-CD versus placebo in treating cocaine dependent individuals.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate to severe cocaine or opioid dependence
  • Willing to enroll in methadone maintenance treatment
  • Demonstrates motivation to stop using cocaine
  • In good general health
  • If female, willing to use an adequate form of contraception for the duration of the study

Exclusion Criteria:

  • Currently suicidal or experiencing psychosis
  • History of psychosis or schizophrenia
  • Inability to read or understand English
  • Current dependence on drugs or alcohol other than cocaine, opiates, or tobacco
  • History of uveitis or ocular abnormalities associated with uveitis
  • Any concomitant disease or abnormalities that, in the opinion of the investigator, may interfere with the study
  • Requires psychotropic medications or steroids within 30 days of study entry
  • Immune deficiency
  • Ongoing active infection
  • HIV infected
  • Pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142857

Locations
United States, Connecticut
VA Connecticut Health Care System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Investigators
Principal Investigator: Thomas R. Kosten, MD Yale University, Department of Psychiatry
  More Information

No publications provided by National Institute on Drug Abuse (NIDA)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00142857     History of Changes
Other Study ID Numbers: NIDA-15477-1, R01-15477-1, DPMC
Study First Received: September 1, 2005
Last Updated: February 19, 2008
Health Authority: United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):
Cocaine Dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Vasoconstrictor Agents
Cardiovascular Agents
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on September 29, 2014